Primate models of Parkinson's disease

被引:25
作者
Collier, TJ [1 ]
Steece-Collier, K [1 ]
Kordower, JH [1 ]
机构
[1] Rush Presbyterian St Lukes Med Ctr, Res Ctr Brain Repair, Dept Neurol Sci, Chicago, IL 60612 USA
关键词
D O I
10.1016/S0014-4886(03)00246-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
引用
收藏
页码:258 / 262
页数:5
相关论文
共 59 条
[1]  
BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5
[2]   THE USE OF L-DOPA IN PARKINSONS-DISEASE - A 20 YEAR FOLLOW-UP [J].
BARBEAU, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1981, 2 (11) :297-299
[3]   Effects of transient focal inactivation of the basal ganglia in parkinsonian primates [J].
Baron, MS ;
Wichmann, T ;
Ma, DM ;
Delong, MR .
JOURNAL OF NEUROSCIENCE, 2002, 22 (02) :592-599
[4]   Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease [J].
Blum, D ;
Torch, S ;
Lambeng, N ;
Nissou, MF ;
Benabid, AL ;
Sadoul, R ;
Verna, JM .
PROGRESS IN NEUROBIOLOGY, 2001, 65 (02) :135-172
[5]  
Brotchie JM, 2000, ANN NEUROL, V47, pS105
[6]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[7]   Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease [J].
Cenci, MA .
AMINO ACIDS, 2002, 23 (1-3) :105-109
[8]   Animal models of neurological deficits: how relevant is the rat? [J].
Cenci, MA ;
Whishaw, IQ ;
Schallert, T .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (07) :574-579
[9]  
COLLIER TJ, 2001, SOC NEUR ABSTR, V27
[10]   Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets [J].
Costa, S ;
Iravani, MM ;
Pearce, RKB ;
Jenner, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 412 (01) :45-50